Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Livzon Pharmaceutical Group ( (HK:1513) ) has provided an update.
Livzon Pharmaceutical Group has revised the terms of reference for its Nomination Committee under the Board, emphasizing compliance with the Hong Kong and Shenzhen Stock Exchange listing rules. The committee will consist of at least three members, primarily independent non-executive directors, ensuring diverse representation and adherence to governance standards. This move is likely to enhance the company’s corporate governance framework, potentially impacting its operational transparency and stakeholder confidence.
The most recent analyst rating on (HK:1513) stock is a Buy with a HK$48.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. operates in the pharmaceutical industry, focusing on the development, production, and distribution of pharmaceutical products. The company is known for its diverse range of healthcare products and services, catering to various medical needs and market segments.
Average Trading Volume: 1,513,250
Technical Sentiment Signal: Buy
Current Market Cap: HK$34.39B
Find detailed analytics on 1513 stock on TipRanks’ Stock Analysis page.